Prostate tumor attenuation in the nu/nu murine model due to anti-sarcosine antibodies in folate-targeted liposomes

Varování

Publikace nespadá pod Fakultu sportovních studií, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

HEGER Zbynek POLANSKÁ Hana RODRIGO Miguel Angel Merlos GURÁŇ Roman KULICH Pavel KOPEL Pavel MASAŘÍK Michal ECKSCHLAGER Tomas STIBOROVA Marie KIZEK Rene ADAM Vojtech

Rok publikování 2016
Druh Článek v odborném periodiku
Časopis / Zdroj Scientific Reports
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www http://www.nature.com/articles/srep33379
Doi http://dx.doi.org/10.1038/srep33379
Obor Onkologie a hematologie
Klíčová slova CANCER PROGRESSION; CELL-LINE; IN-VITRO; METALLOTHIONEIN; EXPRESSION; THERAPY; PROTEIN; URINE; NANOPARTICLES; TRAFFICKING
Přiložené soubory
Popis Herein, we describe the preparation of liposomes with folate-targeting properties for the encapsulation of anti-sarcosine antibodies (antisarAbs@LIP) and sarcosine (sar@LIP). The competitive inhibitory effects of exogenously added folic acid supported the role of folate targeting in liposome internalization. We examined the effects of repeated administration on mice PC-3 xenografts. Sar@LIP treatment significantly increased tumor volume and weight compared to controls treated with empty liposomes. Moreover, antisarAbs@LIP administration exhibited a mild antitumor effect. We also identified differences in gene expression patterns post-treatment. Furthermore, Sar@LIP treatment resulted in decreased amounts of tumor zinc ions and total metallothioneins. Examination of the spatial distribution across the tumor sections revealed a sarcosine-related decline of the MT1X isoform within the marginal regions but an elevation after antisarAbs@LIP administration. Our exploratory results demonstrate the importance of sarcosine as an oncometabolite in PCa. Moreover, we have shown that sarcosine can be a potential target for anticancer strategies in management of PCa.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info